Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17440158 | 0.84 | GAA (0.73) | GAARECQLALDH1A1TDP1CYP1A2 | |
| SCHEMBL14763361 | 0.84 | GAA (0.73) | GAARECQLALDH1A1TDP1CYP1A2 | |
| SCHEMBL6570943 | 0.82 | GAA (0.74) | GAARECQLALDH1A1TDP1CYP1A2 | |
| SCHEMBL24507059 | 0.81 | GAA (0.71) | GAARECQLALDH1A1TDP1CYP1A2 | |
| SCHEMBL22326350 | 0.78 | GAA (0.88) | GAARECQLALDH1A1TDP1CYP1A2 | |
| SCHEMBL29707271 | 0.77 | ALDH1A1 (0.54) | ALDH1A1TDP1CYP1A2MEN1KMT2A | |
| SCHEMBL13509920 | 0.77 | ALDH1A1 (0.54) | ALDH1A1TDP1CYP1A2MEN1KMT2A | |
| SCHEMBL4853171 | 0.76 | GAA (0.65) | GAARECQLALDH1A1TDP1CYP1A2 | |
| SCHEMBL2538210 | 0.76 | GAA (0.65) | GAARECQLALDH1A1TDP1CYP1A2 | |
| SCHEMBL14560518 | 0.76 | TDP1 (0.76) | GAARECQLALDH1A1TDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124562-A1 | Versipelostatin derivative, anti-cancer agent and processes for production of the derivative and agent | TOUDAI TLO, LTD. (JP) | 2009-05-14 | — | — | US | disclosed |
| US-20090124562-A1 | Versipelostatin derivative, anti-cancer agent and processes for production of the derivative and agent | TOUDAI TLO, LTD. (JP) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124562-A1 | Versipelostatin derivative, anti-cancer agent and processes for production of the derivative and agent | HSPA4, GRPR, HSPA5 | GAA 1448/4885RECQL 4695/4885ALDH1A1 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.